E-LIB Suche - Ergebnisse für: Matter-Walstra, Klazien

1

Clinical characteristics and therapeutic behavior of breast..:

Krüerke, Daniel ; Schenker, Marianne ; Matter-Walstra, Klazien
BMC Complementary Medicine and Therapies. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

2

Handling Uncertainty in Cost-Effectiveness Analysis: Budget..:

Sendi, Pedram ; Matter-Walstra, Klazien ; Schwenkglenks, Matthias
Healthcare. 9 (2021) 11 - p. 1419 , 2021

Link: https://doi.org/10.3390/..

3

Cost-effectiveness and resource allocation (CERA) 18 years ..:

Jakovljevic, Mihajlo ; Matter-Walstra, Klazien ; Sugahara, Takuma...
Cost Effectiveness and Resource Allocation. 18 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

4

Impact of treatment decision algorithms on treatment costs ..:

Panje, Cdric M. ; Putora, Paul M. ; Hundsberger, Thomas...
Swiss Medical Weekly. , 2019

Link: https://doi.org/10.4414/..

5

Impact of a Surgical Sealing Patch on Lymphatic Drainage Af..:

for the Swiss Group for Clinical Cancer Research (SAKK) ; Weber, Walter Paul ; Tausch, Christoph...
Annals of Surgical Oncology. 25 (2018) 9 - p. 2632-2640 , 2018

Link: https://doi.org/10.1245/..

6

A cost-effectiveness analysis of consolidative local therap..:

Panje, Cedric M. ; Dedes, Konstantin J. ; Matter-Walstra, Klazien...
Radiotherapy and Oncology. 129 (2018) 2 - p. 257-263 , 2018

Link: https://doi.org/10.1016/..

7

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Main..:

Gautschi, Oliver ; Rothschild, Sacha I. ; Li, Qiyu...
Clinical Lung Cancer. 18 (2017) 3 - p. 303-309 , 2017

Link: https://doi.org/10.1016/..

8

P3.07-001 Nivolumab for Patients with Advanced Non-Squamous..:

Matter-Walstra, Klazien ; Schwenkglenks, Matthias ; Aebi, Stefan...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S1430-S1431 , 2017

Link: https://doi.org/10.1016/..

9

Bevacizumab Continuation Versus Treatment Holidays After Fi..:

Matter-Walstra, Klazien ; Schwenkglenks, Matthias ; Betticher, Daniel...
Clinical Colorectal Cancer. 15 (2016) 4 - p. 314-320.e2 , 2016

Link: https://doi.org/10.1016/..

10

SAKK 24/09: safety and tolerability of bevacizumab plus pac..:

on behalf of the Swiss Group for Clinical Cancer Research (SAKK) ; Rochlitz, Christoph ; Bigler, Martin...
BMC Cancer. 16 (2016) 1 - p. , 2016

Link: https://doi.org/10.1186/..

11

End-of-life costs of medical care for advanced stage cancer..:

Kovacevic, Aleksandra ; Dragojevic-Simic, Viktorija ; Rancic, Nemanja...
Vojnosanitetski pregled; Military Medical and Pharmaceutical Journal of Serbia. 72 (2015) 4 - p. 334-341 , 2015

Link: https://doi.org/10.2298/..

12

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Val..:

Matter-Walstra, Klazien ; Klingbiel, Dirk ; Szucs, Thomas..
PharmacoEconomics. 32 (2014) 6 - p. 591-599 , 2014

Link: https://doi.org/10.1007/..

13

Cost-Effectiveness of Maintenance Pemetrexed in Patients wi..:

Matter-Walstra, Klazien ; Joerger, Markus ; Kühnel, Ursula...
Value in Health. 15 (2012) 1 - p. 65-71 , 2012

Link: https://doi.org/10.1016/..

14

Bevacizumab in combination with paclitaxel for HER-2 negati..:

Dedes, Konstantin J. ; Matter-Walstra, Klazien ; Schwenkglenks, Matthias...
European Journal of Cancer. 45 (2009) 8 - p. 1397-1406 , 2009

Link: https://doi.org/10.1016/..

15

Analysis of patient flows for orthopedic procedures using s..:

Matter-Walstra, Klazien ; Widmer, Marcel ; Busato, André
BMC Health Services Research. 6 (2006) 1 - p. , 2006

Link: https://doi.org/10.1186/..